2012 © Institute for Molecular Medicine Finland FIMM
Biobanking policies
Biobanking procedures will be conducted in accordance with international ethical recommendations, as well as international and national biobanking guidelines. Best practices will be followed, the most important being the BBMRI process and the build-up of Finnish participation in the BBMRI network (BBMRI.fi).
The researchers intending to collect new sample material and utilize the services of the FIMM biobank are required to conduct their studies in accordance with Good Clinical Practice (GCP) protocols. The protocol including any amendments and the subject informed consent have to receive an institutional review board/independent ethics committee favourable opinion before initiation of the study.
Policies for sample storage
The Biobank will honour the rights and interests of individual principal investigators, propagating the possibilities of collaboration and optimal use of the public resources and human samples in the most cost-effective way. Thus, by keeping a registry of existing samples in the biobank, there will be interesting possibilities to create comparative studies, provide control specimens and explore e.g. a given biomarker in new indications.
- Collaboration is based on a written agreement.
-
No change in the ownership of the samples.
-
No change in the decision making process on the sample use. If FIMM participates in the costs, decision making will be a joint procedure.
-
Costs covered by a fee to the owner of the sample collection.
-
The sample collections will be published in a so called availability database (under development) for researchers and for patients/sample donors and to promote awareness and collaborations.
-
Access to biobanked samples through dedicated FIMM personnel.
